-
2024-511855-16-00
5
2019-07-25
Onco-hematology
-
2024-519620-24-01
5
2026-06-01
ANCA-associated vasculitis
-
2025-520652-28-00
1
2026-05-04
healthy participants
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2024-520205-39-00
5
2026-04-21
Traumatic brain injury
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2025-521286-27-00
10
2026-03-26
Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimm
-
2024-513750-30-00
4
2026-03-25
Sickle Cell Disease
-
2024-520128-27-00
4
2026-03-04
colorectal adenocarcinoma
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-514400-14-00
4
2026-01-23
liver transplanted patients with advanced hepatocellular carcinoma
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2022-501557-36-00
4
2025-12-19
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-520780-40-00
4
2025-11-26
Primary Mebranous Nephropathy (PMN)
-
2024-514401-54-00
5
2025-11-13
Chronic Primary Immune Thrombocytopenia
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-519495-83-00
4
2025-10-28
Digestive system diseases